Biocon Receives FDA Form 483 After Bengaluru Biosimilars Site Inspection

Biocon Ltd has confirmed that the US FDA completed its pre-license inspection at the company’s biosimilars site in Bengaluru, resulting in a Form 483 with five observations. The company stated it will work closely with the regulator to address the issues raised and ensure compliance with global quality standards.

Inspection Details

The Form 483 observations highlight areas where the FDA believes improvements are needed in Biocon’s manufacturing and quality processes. While such observations are not uncommon, they require timely corrective actions to progress toward product approvals.

Strategic Significance

The inspection is part of Biocon’s efforts to expand its biosimilars portfolio in the US market, a key growth driver for the company. Addressing the FDA’s observations effectively will be crucial for Biocon’s regulatory approvals and long-term positioning in the global biopharmaceutical sector.

Key highlights

• FDA issues Form 483 with five observations
• Inspection conducted at Biocon’s Bengaluru biosimilars site
• Company to implement corrective measures promptly
• Critical step toward US biosimilars approval

Sources: Reuters, Company statement